Search Results

There are 71734 results for: content related to: Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study

  1. You have free access to this content
    Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood

    British Journal of Pharmacology

    Volume 173, Issue 16, August 2016, Pages: 2490–2505, Javier Calleja-Conde, Victor Echeverry-Alzate, Elena Giné, Kora-Mareen Bühler, Roser Nadal, Rafael Maldonado, Fernando Rodríguez de Fonseca, Antoni Gual and Jose Antonio López-Moreno

    Version of Record online : 18 JUL 2016, DOI: 10.1111/bph.13526

  2. You have full text access to this OnlineOpen article
    Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers


    Volume 111, Issue 8, August 2016, Pages: 1477–1487, Niamh Fitzgerald, Kathryn Angus, Andrew Elders, Marisa de Andrade, Duncan Raistrick, Nick Heather and Jim McCambridge

    Version of Record online : 5 JUN 2016, DOI: 10.1111/add.13438

  3. Opioid antagonists for alcohol dependence

    Intervention Review

    The Cochrane Library

    Susanne Rösner, Andrea Hackl-Herrwerth, Stefan Leucht, Simona Vecchi, Manit Srisurapanont and Michael Soyka

    Published Online : 8 DEC 2010, DOI: 10.1002/14651858.CD001867.pub3

  4. You have free access to this content
    Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate


    Clément Palpacuer, Renan Duprez, Alexandre Huneau, Clara Locher, Rémy Boussageon, Bruno Laviolle and Florian Naudet

    Version of Record online : 20 SEP 2017, DOI: 10.1111/add.13974

  5. You have free access to this content
    Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy

    British Journal of Clinical Pharmacology

    Volume 81, Issue 2, February 2016, Pages: 290–300, Lars-Erik Broksoe Kyhl, Shen Li, Kirstine Ullitz Faerch, Birgitte Soegaard, Frank Larsen and Johan Areberg

    Version of Record online : 27 JAN 2016, DOI: 10.1111/bcp.12805

  6. Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder

    Journal of Clinical Pharmacy and Therapeutics

    Volume 41, Issue 1, February 2016, Pages: 97–100, G. Milano, V. Zavan, W. M. Natta, A. Martelli and F. Mattioli

    Version of Record online : 30 DEC 2015, DOI: 10.1111/jcpt.12345

  7. The Opioid Receptor Antagonist Nalmefene Reduces Responding Maintained by Ethanol Presentation: Preclinical Studies in Ethanol-Preferring and Outbred Wistar Rats

    Alcoholism: Clinical and Experimental Research

    Volume 22, Issue 9, December 1998, Pages: 2174–2185, Harry L June, Collette Grey, Connease Warren-Reese, La Franze Durr, Anila Ricks-Cord, Amanda Johnson, Shannan McCane, LaShone Williams, Dynesha Mason, Rancia Cummings and Amanda Lawrence

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1530-0277.1998.tb05931.x

  8. Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers

    Alcoholism: Clinical and Experimental Research

    Volume 32, Issue 7, July 2008, Pages: 1159–1166, Albert J. Arias, Stephen Armeli, Joel Gelernter, Jonathan Covault, Antero Kallio, Sakari Karhuvaara, Tiina Koivisto, Rauno Mäkelä and Henry R. Kranzler

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1530-0277.2008.00735.x

  9. A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence

    Alcoholism: Clinical and Experimental Research

    Volume 18, Issue 5, October 1994, Pages: 1162–1167, Barbara J. Mason, Eva C. Ritvo, Robert O. Morgan, Femando R. Salvato, Gloria Goldberg, Bruce Welch and Emilio Mantero-Atienza

    Version of Record online : 11 APR 2006, DOI: 10.1111/j.1530-0277.1994.tb00098.x

  10. Effects of liver disease on the disposition of the opioid antagonist nalmefene

    Clinical Pharmacology & Therapeutics

    Volume 61, Issue 1, January 1997, Pages: 15–23, Reginald F. Frye, Gary R. Matzke, Robert Schade, Rosina Dixon and Mordechai Rabinovitz

    Version of Record online : 8 FEB 1997, DOI: 10.1016/S0009-9236(97)90178-8

  11. You have free access to this content
    Open-label trial of oral nalmefene therapy for the pruritus of cholestasis


    Volume 27, Issue 3, March 1998, Pages: 679–684, Nora V. Bergasa, Joseph M. Schmitt, Thomas L. Talbot, David W. Alling, Mark G. Swain, Maria L. Turner, Janice B. Jenkins and E. Anthony Jones

    Version of Record online : 30 DEC 2003, DOI: 10.1002/hep.510270307

  12. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine

    Fundamental & Clinical Pharmacology

    Volume 31, Issue 5, October 2017, Pages: 574–579, Melissa Yéléhé-Okouma, Hervé Martini, Jérémie Lemarié, Pierre Labroca, Nadine Petitpain, Valérie Gibaja, François Paille and Pierre Gillet

    Version of Record online : 9 MAY 2017, DOI: 10.1111/fcp.12286

  13. The Effect of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Nalmefene

    The Journal of Clinical Pharmacology

    Volume 36, Issue 2, February 1996, Pages: 144–151, Dr. Gary R. Matzke, Dr. Reginald F. Frye, Dr. Alicia C. M. Alexander, Ms. Robin Reynolds, Dr. Rosina Dixon, Dr. James Johnston and Dr. Raymond M. Rault

    Version of Record online : 8 MAR 2013, DOI: 10.1002/j.1552-4604.1996.tb04179.x

  14. Nalmefene to Prevent Epidural Narcotic Side Effects in Pediatric Patients: A Pharmacokinetic and Safety Study

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 7, July 2000, Pages: 745–749, Dr. David A. Rosen, Mr. John L. Morris, Dr. Kathleen R. Rosen, Dr. Elizabeth R. Nelson, Dr. Robert J. Steelman, Dr. Robert A. Gustafson, Dr. Jeffrey A. Wilhelm, Dr. Cheng T. Chang, Mr. Jeffrey W. Thackara and Dr. Reginald F. Frye

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.20.9.745.35207

  15. Nalmefene Causes Greater Hypothalamic-Pituitary-Adrenal Axis Activation than Naloxone in Normal Volunteers: Implications for the Treatment of Alcoholism

    Alcoholism: Clinical and Experimental Research

    Volume 22, Issue 7, October 1998, Pages: 1430–1436, James H. Schluger, Ann Ho, Lisa Borg, Margaret Porter, Swapnil Maniar, Mithat Gunduz, Guillaurne Perret, Andrea King and Mary Jeanne Kreek

    Version of Record online : 30 MAY 2006, DOI: 10.1111/j.1530-0277.1998.tb03931.x

  16. You have free access to this content
    The effect of age on the pharmacokinetics of the opioid antagonist nalmefene

    British Journal of Clinical Pharmacology

    Volume 42, Issue 3, September 1996, Pages: 301–306, R. F. FRYE, G. R. MATZKE, N. S. JALLAD, J. A. WILHELM and G. B. BIKHAZI

    Version of Record online : 2 OCT 2003, DOI: 10.1046/j.1365-2125.1996.04133.x

  17. Human pharmacology and abuse potential of nalmefene

    Clinical Pharmacology & Therapeutics

    Volume 49, Issue 3, March 1991, Pages: 300–306, Paul J Fudala, Stephen J Heishman, Jack E Henningfield and Rolley E Johnson

    Version of Record online : 10 MAR 1991, DOI: 10.1038/clpt.1991.32

  18. Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist

    The Journal of Clinical Pharmacology

    Volume 27, Issue 3, March 1987, Pages: 233–239, Dr. Ross Dixon, Mr. Joseph Gentile, Dr. Hon-Bin Hsu, Dr. Jane Hsiao, Dr. John Howes, Dr. Dyal Garg and Dr. Donald Weidler

    Version of Record online : 8 MAR 2013, DOI: 10.1002/j.1552-4604.1987.tb02191.x

  19. Prolonged blockade of opioid effect with oral nalmefene

    Clinical Pharmacology & Therapeutics

    Volume 40, Issue 5, November 1986, Pages: 537–542, Thomas J Gal, Cosmo A DiFazio and Ross Dixon

    Version of Record online : 1 NOV 1986, DOI: 10.1038/clpt.1986.220

  20. Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers

    Alcoholism: Clinical and Experimental Research

    Volume 28, Issue 9, September 2004, Pages: 1362–1370, David J. Drobes, Raymond F. Anton, Suzanne E. Thomas and Konstantin Voronin

    Version of Record online : 3 MAY 2006, DOI: 10.1097/01.ALC.0000139704.88862.01